OBJECTIVE: Human papillomavirus (HPV), particularly HPV16, is a causative agent for 25% of head and neck squamous cell cancer, including laryngeal squamous cell cancer (LSCC). HPV-positive (HPV+ve) patients, particularly those with oropharyngeal SCC, have improved prognosis. For LSCC patients, this remains to be established. The goal was to determine stage and survival outcomes in LSCC in the context of HPV infection. STUDY DESIGN: Historical cohort study. SETTING: Primary care academic health system. SUBJECTS AND METHODS: In 79 patients with primary LSCC, HPV was determined using real-time quantitative polymerase chain reaction. χ(2) or Fisher exact test was used to test the association of HPV+ve with 21 risk factors including race, stage, gender, age, smoking, alcohol, treatment, and health insurance. Kaplan-Meier and log-rank tests were used to study the association of HPV and LSCC survival outcome. RESULTS: HPV16 was detected in 27% of LSCC patients. Caucasian American (CA) patients had higher HPV prevalence (33%) than did African American (AA) LSCC patients (16%; P = .058). HPV was significantly associated with gender (P = .016) and insurance type (P = .001). There were no differences in survival between HPV+ve and HPV-negative (HPV-ve) patients. There was no association with HPV and other risk factors including stage (early vs late). CONCLUSION: We found a high prevalence of HPV in men and a lower prevalence of HPV infection in AA compared with CA. Despite the strikingly better survival of patients with HPV+ve oropharyngeal tumors, even when adjusted for smoking, this correlation does not seem to hold true in the larynx. Larger multiethnic LSCC cohorts are needed to more clearly delineate HPV-related survival across ethnicities.
OBJECTIVE:Human papillomavirus (HPV), particularly HPV16, is a causative agent for 25% of head and neck squamous cell cancer, including laryngeal squamous cell cancer (LSCC). HPV-positive (HPV+ve) patients, particularly those with oropharyngeal SCC, have improved prognosis. For LSCC patients, this remains to be established. The goal was to determine stage and survival outcomes in LSCC in the context of HPV infection. STUDY DESIGN: Historical cohort study. SETTING: Primary care academic health system. SUBJECTS AND METHODS: In 79 patients with primary LSCC, HPV was determined using real-time quantitative polymerase chain reaction. χ(2) or Fisher exact test was used to test the association of HPV+ve with 21 risk factors including race, stage, gender, age, smoking, alcohol, treatment, and health insurance. Kaplan-Meier and log-rank tests were used to study the association of HPV and LSCC survival outcome. RESULTS:HPV16 was detected in 27% of LSCC patients. Caucasian American (CA) patients had higher HPV prevalence (33%) than did African American (AA) LSCC patients (16%; P = .058). HPV was significantly associated with gender (P = .016) and insurance type (P = .001). There were no differences in survival between HPV+ve and HPV-negative (HPV-ve) patients. There was no association with HPV and other risk factors including stage (early vs late). CONCLUSION: We found a high prevalence of HPV in men and a lower prevalence of HPV infection in AA compared with CA. Despite the strikingly better survival of patients with HPV+ve oropharyngeal tumors, even when adjusted for smoking, this correlation does not seem to hold true in the larynx. Larger multiethnic LSCC cohorts are needed to more clearly delineate HPV-related survival across ethnicities.
Authors: Y M Lo; M S Tein; T K Lau; C J Haines; T N Leung; P M Poon; J S Wainscoat; P J Johnson; A M Chang; N M Hjelm Journal: Am J Hum Genet Date: 1998-04 Impact factor: 11.025
Authors: Patrick K Ha; Sara I Pai; William H Westra; Maura L Gillison; Betty C Tong; David Sidransky; Joseph A Califano Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: V G Gorgoulis; P Zacharatos; A Kotsinas; A Kyroudi; A N Rassidakis; J A Ikonomopoulos; C Barbatis; C S Herrington; C Kittas Journal: Hum Pathol Date: 1999-03 Impact factor: 3.466
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Rolando Herrero; Xavier Castellsagué; Michael Pawlita; Jolanta Lissowska; Frank Kee; Prabda Balaram; Thangarajan Rajkumar; Hema Sridhar; Barbara Rose; Javier Pintos; Leticia Fernández; Ali Idris; María José Sánchez; Adoración Nieto; Renato Talamini; Alessandra Tavani; F Xavier Bosch; Ulrich Reidel; Peter J F Snijders; Chris J L M Meijer; Raphael Viscidi; Nubia Muñoz; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506
Authors: Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Oral Oncol Date: 2017-12-23 Impact factor: 5.337
Authors: Maria J Worsham; Josena K Stephen; Kang Mei Chen; Meredith Mahan; Vanessa Schweitzer; Shaleta Havard; George Divine Journal: Clin Cancer Res Date: 2013-03-26 Impact factor: 12.531
Authors: Maria J Worsham; Kang Mei Chen; Tamer Ghanem; Josena K Stephen; George Divine Journal: Otolaryngol Head Neck Surg Date: 2013-06-04 Impact factor: 3.497
Authors: Kang Mei Chen; Josena K Stephen; Tamer Ghanem; Robert Stachler; Glendon Gardner; Lamont Jones; Vanessa P Schweitzer; Francis Hall; George Divine; Maria J Worsham Journal: Otolaryngol Head Neck Surg Date: 2013-01-08 Impact factor: 3.497